For the Inventor, By the Inventor

Enter assignee name

Houston, TX, United States of America

Bellicum Pharmaceuticals, Inc.

USPTO Granted Patents = 9

% Expired Patents = 11.1

EPO Patents = 5

Trademarks = 2

Forward Citations = 76

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

David Spencer (9 out of 27 patents)

Aaron Edward Foster (6 out of 7 patents)

Kevin Slawin (6 out of 15 patents)

4. Wei-Chun Chang (2 out of 2 patents)

5. Matthew Robert Collinson-Pautz (1 out of 1 patent)

6. Natalia Lapteva (1 out of 2 patents)

7. Dongsu Park (1 out of 1 patent)

8. Annemarie Moseley (2 patents)

9. Kevin M Slawin (0 patent)

10. Matthew R Collinson-pautz (0 patent)

11. Joseph Henri Bayle (1 patent)

12. David M Spencer (0 patent)

13. Mylinh Duong (0 patent)

9 patents: Sort by Forward Citations

1. 11839647 - Methods for inducing partial apoptosis using caspase polypeptides (2023-12-12),

2. 10934346 - Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 (2021-03-02),

3. 10888608 - Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides (2021-01-12),

4. 10525110 - Methods for inducing partial apoptosis using caspase polypeptides (2020-01-07),

5. 9944690 - Methods for controlling T cell proliferation (2018-04-17),

6. 9932572 - Modified Caspase polypeptides and uses thereof (2018-04-03),

7. 9913882 - Methods for inducing partial apoptosis using caspase polypeptides (2018-03-13),

8. 9434935 - Modified caspase polypeptides and uses thereof (2016-09-06),

9. 8486693 - Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods (2013-07-16),

Bellicum Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing novel cellular immunotherapies for various forms of cancer and other serious diseases. Their leading product candidates include BPX-501 and BPX-601, which are designed to improve immune cell therapies by controlling immune reactions and enhancing their efficacy. Bellicum is committed to advancing innovative treatments that have the potential to address unmet medical needs and improve patient outcomes.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Bellicum Pharmaceuticals, Inc.

9 Patents

#513 in Houston, TX

#2,057 in Texas

#32,549 in US

Houston, TX, United States of America

Bellicum Pharmaceuticals, Inc.

Forward Citations = 76

7 inventors:

David Spencer (9 out of 27 patents)

Aaron Edward Foster (6 out of 7 patents)

Kevin Slawin (6 out of 15 patents)

4. Wei-Chun Chang (2 out of 2 patents)

5. Matthew Robert Collinson-Pautz (1 out of 1 patent)

Please report any incorrect information to [email protected]

Loading…